XML 53 R29.htm IDEA: XBRL DOCUMENT
v3.21.2

Segments of Business and Geographic Areas (Tables) | 3 Months Ended | 9 Months Ended
--- | --- | ---
Oct. 03, 2021 | Oct. 03, 2021
Segment Reporting [Abstract] |  |
Sales By Segment Of Business |  | SALES BY SEGMENT OF BUSINESS
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | October 3, 2021 |  | September 27, 2020 |  | Percent Change |  | October 3, 2021 |  | September 27, 2020 |  | Percent Change
Consumer Health |  |  |  |  |  |  |  |  |  |  |  |
OTC |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 686 |  |  | 601 |  |  | 14.0 | % |  | $ | 1,960 |  |  | 1,917 |  |  | 2.2 | %
International |  | 686 |  |  | 541 |  |  | 26.9 |  |  | 1,894 |  |  | 1,722 |  |  | 10.0 |
Worldwide |  | 1,372 |  |  | 1,142 |  |  | 20.1 |  |  | 3,854 |  |  | 3,639 |  |  | 5.9 |
Skin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 569 |  |  | 572 |  |  | (0.5) |  |  | 1,862 |  |  | 1,767 |  |  | 5.4 |
International |  | 555 |  |  | 577 |  |  | (3.8) |  |  | 1,595 |  |  | 1,506 |  |  | 5.9 |
Worldwide |  | 1,124 |  |  | 1,149 |  |  | (2.2) |  |  | 3,457 |  |  | 3,273 |  |  | 5.6 |
Oral Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 150 |  |  | 164 |  |  | (8.4) |  |  | 478 |  |  | 510 |  |  | (6.2) |
International |  | 248 |  |  | 248 |  |  | 0.1 |  |  | 762 |  |  | 694 |  |  | 9.9 |
Worldwide |  | 398 |  |  | 412 |  |  | (3.3) |  |  | 1,240 |  |  | 1,204 |  |  | 3.0 |
Baby Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 95 |  |  | 91 |  |  | 5.2 |  |  | 288 |  |  | 279 |  |  | 3.3 |
International |  | 296 |  |  | 302 |  |  | (2.0) |  |  | 879 |  |  | 831 |  |  | 5.8 |
Worldwide |  | 391 |  |  | 393 |  |  | (0.3) |  |  | 1,167 |  |  | 1,110 |  |  | 5.2 |
Women's Health |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  |  | 3 |  |  | 20.1 |  |  | 9 |  |  | 10 |  |  | (5.7) |
International |  | 229 |  |  | 227 |  |  | 0.5 |  |  | 675 |  |  | 654 |  |  | 3.1 |
Worldwide |  | 232 |  |  | 230 |  |  | 0.8 |  |  | 684 |  |  | 664 |  |  | 3.0 |
Wound Care/Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 122 |  |  | 125 |  |  | (2.6) |  |  | 390 |  |  | 370 |  |  | 5.3 |
International |  | 61 |  |  | 64 |  |  | (5.2) |  |  | 186 |  |  | 175 |  |  | 5.8 |
Worldwide |  | 182 |  |  | 189 |  |  | (3.5) |  |  | 575 |  |  | 545 |  |  | 5.4 |
TOTAL Consumer Health |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,625 |  |  | 1,556 |  |  | 4.5 |  |  | 4,987 |  |  | 4,853 |  |  | 2.8 |
International |  | 2,075 |  |  | 1,958 |  |  | 5.9 |  |  | 5,991 |  |  | 5,582 |  |  | 7.3 |
Worldwide |  | 3,700 |  |  | 3,514 |  |  | 5.3 |  |  | 10,978 |  |  | 10,435 |  |  | 5.2 |
PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,771 |  |  | 2,558 |  |  | 8.3 |  |  | 7,932 |  |  | 7,330 |  |  | 8.2 |
International |  | 1,480 |  |  | 1,230 |  |  | 20.3 |  |  | 4,464 |  |  | 3,619 |  |  | 23.3 |
Worldwide |  | 4,250 |  |  | 3,789 |  |  | 12.2 |  |  | 12,395 |  |  | 10,950 |  |  | 13.2 |
REMICADE® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 480 |  |  | 634 |  |  | (24.3) |  |  | 1,508 |  |  | 1,852 |  |  | (18.6) |
U.S. Exports |  | 47 |  |  | 78 |  |  | (40.2) |  |  | 197 |  |  | 321 |  |  | (38.7) |
International |  | 234 |  |  | 209 |  |  | 12.2 |  |  | 721 |  |  | 673 |  |  | 7.1 |
Worldwide |  | 761 |  |  | 921 |  |  | (17.4) |  |  | 2,426 |  |  | 2,846 |  |  | (14.8) |
SIMPONI / SIMPONI ARIA® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 295 |  |  | 312 |  |  | (5.3) |  |  | 840 |  |  | 840 |  |  | 0.0 |
International |  | 276 |  |  | 280 |  |  | (1.1) |  |  | 877 |  |  | 827 |  |  | 6.1 |
Worldwide |  | 571 |  |  | 592 |  |  | (3.3) |  |  | 1,717 |  |  | 1,667 |  |  | 3.0 |
STELARA® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,569 |  |  | 1,313 |  |  | 19.5 |  |  | 4,396 |  |  | 3,668 |  |  | 19.9 |
International |  | 809 |  |  | 634 |  |  | 27.7 |  |  | 2,404 |  |  | 1,795 |  |  | 33.9 |
Worldwide |  | 2,378 |  |  | 1,947 |  |  | 22.2 |  |  | 6,800 |  |  | 5,463 |  |  | 24.5 |
TREMFYA® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 376 |  |  | 222 |  |  | 69.7 |  |  | 975 |  |  | 650 |  |  | 50.1 |
International |  | 161 |  |  | 105 |  |  | 52.5 |  |  | 459 |  |  | 316 |  |  | 45.4 |
Worldwide |  | 537 |  |  | 327 |  |  | 64.1 |  |  | 1,434 |  |  | 965 |  |  | 48.5 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  |  | — |  |  | * |  | 15 |  |  | — |  |  | *
International |  | 0 |  |  | 3 |  |  | * |  | 3 |  |  | 9 |  |  | (68.6) |
Worldwide |  | 3 |  |  | 3 |  |  | (26.4) |  |  | 18 |  |  | 9 |  |  | 91.6 |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 679 |  |  | 413 |  |  | 64.3 |  |  | 1,635 |  |  | 1,265 |  |  | 29.2 |
International |  | 709 |  |  | 451 |  |  | 57.2 |  |  | 1,788 |  |  | 1,397 |  |  | 28.0 |
Worldwide |  | 1,389 |  |  | 864 |  |  | 60.6 |  |  | 3,424 |  |  | 2,662 |  |  | 28.6 |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 270 |  |  | — |  |  | * |  | 421 |  |  | — |  |  | *
International |  | 233 |  |  | — |  |  | * |  | 346 |  |  | — |  |  | *
Worldwide |  | 502 |  |  | — |  |  | * |  | 766 |  |  | — |  |  | *
EDURANT® / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 12 |  |  | 11 |  |  | 8.4 |  |  | 31 |  |  | 33 |  |  | (4.8) |
International |  | 247 |  |  | 226 |  |  | 9.7 |  |  | 733 |  |  | 684 |  |  | 7.2 |
Worldwide |  | 259 |  |  | 236 |  |  | 9.6 |  |  | 764 |  |  | 716 |  |  | 6.7 |
PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 380 |  |  | 379 |  |  | 0.4 |  |  | 1,128 |  |  | 1,154 |  |  | (2.2) |
International |  | 137 |  |  | 147 |  |  | (7.1) |  |  | 440 |  |  | 461 |  |  | (4.6) |
Worldwide |  | 517 |  |  | 526 |  |  | (1.7) |  |  | 1,568 |  |  | 1,615 |  |  | (2.9) |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 18 |  |  | 24 |  |  | (26.0) |  |  | 55 |  |  | 79 |  |  | (29.6) |
International |  | 93 |  |  | 78 |  |  | 18.3 |  |  | 270 |  |  | 252 |  |  | 6.9 |
Worldwide |  | 110 |  |  | 102 |  |  | 7.8 |  |  | 325 |  |  | 331 |  |  | (1.8) |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 835 |  |  | 759 |  |  | 10.2 |  |  | 2,448 |  |  | 2,285 |  |  | 7.2 |
International |  | 854 |  |  | 846 |  |  | 0.8 |  |  | 2,770 |  |  | 2,565 |  |  | 8.0 |
Worldwide |  | 1,689 |  |  | 1,605 |  |  | 5.3 |  |  | 5,218 |  |  | 4,850 |  |  | 7.6 |
CONCERTA® / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 35 |  |  | 43 |  |  | (19.5) |  |  | 117 |  |  | 150 |  |  | (22.1) |
International |  | 122 |  |  | 107 |  |  | 14.2 |  |  | 372 |  |  | 319 |  |  | 16.4 |
Worldwide |  | 157 |  |  | 149 |  |  | 4.5 |  |  | 489 |  |  | 469 |  |  | 4.1 |
INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 648 |  |  | 585 |  |  | 11.0 |  |  | 1,882 |  |  | 1,704 |  |  | 10.4 |
International |  | 355 |  |  | 341 |  |  | 4.3 |  |  | 1,111 |  |  | 983 |  |  | 13.0 |
Worldwide |  | 1,004 |  |  | 926 |  |  | 8.5 |  |  | 2,994 |  |  | 2,688 |  |  | 11.4 |
RISPERDAL CONSTA® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 71 |  |  | 70 |  |  | 1.3 |  |  | 210 |  |  | 220 |  |  | (4.7) |
International |  | 69 |  |  | 81 |  |  | (16.7) |  |  | 242 |  |  | 254 |  |  | (5.1) |
Worldwide |  | 140 |  |  | 152 |  |  | (8.4) |  |  | 452 |  |  | 475 |  |  | (4.9) |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 81 |  |  | 60 |  |  | 34.7 |  |  | 239 |  |  | 210 |  |  | 13.9 |
International |  | 307 |  |  | 317 |  |  | (2.9) |  |  | 1,045 |  |  | 1,008 |  |  | 3.7 |
Worldwide |  | 388 |  |  | 377 |  |  | 3.1 |  |  | 1,284 |  |  | 1,218 |  |  | 5.5 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,525 |  |  | 1,267 |  |  | 20.3 |  |  | 4,364 |  |  | 3,623 |  |  | 20.4 |
International |  | 2,140 |  |  | 1,862 |  |  | 14.9 |  |  | 6,406 |  |  | 5,310 |  |  | 20.6 |
Worldwide |  | 3,665 |  |  | 3,129 |  |  | 17.1 |  |  | 10,770 |  |  | 8,933 |  |  | 20.6 |
DARZALEX® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 841 |  |  | 585 |  |  | 43.7 |  |  | 2,302 |  |  | 1,540 |  |  | 49.5 |
International |  | 739 |  |  | 514 |  |  | 43.7 |  |  | 2,076 |  |  | 1,397 |  |  | 48.6 |
Worldwide |  | 1,580 |  |  | 1,099 |  |  | 43.7 |  |  | 4,378 |  |  | 2,937 |  |  | 49.1 |
ERLEADA® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 214 |  |  | 152 |  |  | 40.5 |  |  | 578 |  | 407 |  | 41.8 |
International |  | 130 |  |  | 55 |  |  | * |  | 329 |  | 112 |  | *
Worldwide |  | 344 |  |  | 206 |  |  | 66.7 |  |  | 907 |  | 519 |  | 74.7 |
IMBRUVICA® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 413 |  |  | 450 |  |  | (8.3) |  |  | 1,311 |  |  | 1,329 |  |  | (1.3) |
International |  | 654 |  |  | 581 |  |  | 12.6 |  |  | 1,996 |  |  | 1,682 |  |  | 18.7 |
Worldwide |  | 1,066 |  |  | 1,031 |  |  | 3.5 |  |  | 3,307 |  |  | 3,011 |  |  | 9.9 |
ZYTIGA® / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 25 |  |  | 58 |  |  | (57.0) |  |  | 96 |  |  | 284 |  |  | (66.2) |
International |  | 523 |  |  | 532 |  |  | (1.8) |  |  | 1,653 |  |  | 1,564 |  |  | 5.7 |
Worldwide |  | 548 |  |  | 590 |  |  | (7.2) |  |  | 1,749 |  |  | 1,848 |  |  | (5.4) |
OTHER ONCOLOGY(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 32 |  |  | 21 |  |  | 49.6 |  |  | 76 |  |  | 63 |  |  | 21.0 |
International |  | 94 |  |  | 181 |  |  | (48.0) |  |  | 352 |  |  | 556 |  |  | (36.6) |
Worldwide |  | 126 |  |  | 203 |  |  | (37.6) |  |  | 428 |  |  | 619 |  |  | (30.7) |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 610 |  |  | 510 |  |  | 19.7 |  |  | 1,778 |  |  | 1,541 |  |  | 15.4 |
International |  | 258 |  |  | 239 |  |  | 7.9 |  |  | 821 |  |  | 742 |  |  | 10.7 |
Worldwide |  | 868 |  |  | 749 |  |  | 15.9 |  |  | 2,599 |  |  | 2,283 |  |  | 13.9 |
OPSUMIT® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 299 |  |  | 244 |  |  | 22.8 |  |  | 861 |  |  | 729 |  |  | 18.2 |
International |  | 159 |  |  | 148 |  |  | 7.4 |  |  | 510 |  |  | 458 |  |  | 11.3 |
Worldwide |  | 458 |  |  | 392 |  |  | 17.0 |  |  | 1,371 |  |  | 1,187 |  |  | 15.5 |
UPTRAVI® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 265 |  |  | 226 |  |  | 17.3 |  |  | 792 |  |  | 692 |  |  | 14.6 |
International |  | 44 |  |  | 34 |  |  | 30.4 |  |  | 135 |  |  | 100 |  |  | 34.6 |
Worldwide |  | 309 |  |  | 260 |  |  | 19.0 |  |  | 927 |  |  | 792 |  |  | 17.1 |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 47 |  |  | 40 |  |  | 14.4 |  |  | 125 |  |  | 121 |  |  | 2.8 |
International |  | 54 |  |  | 57 |  |  | (4.4) |  |  | 176 |  |  | 183 |  |  | (3.7) |
Worldwide |  | 101 |  |  | 97 |  |  | 3.4 |  |  | 301 |  |  | 304 |  |  | (1.1) |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 800 |  |  | 931 |  |  | (14.0) |  |  | 2,379 |  |  | 2,574 |  |  | (7.6) |
International |  | 333 |  |  | 351 |  |  | (5.1) |  |  | 1,007 |  |  | 1,052 |  |  | (4.2) |
Worldwide |  | 1,133 |  |  | 1,281 |  |  | (11.5) |  |  | 3,386 |  |  | 3,625 |  |  | (6.6) |
XARELTO® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 636 |  |  | 630 |  |  | 0.8 |  |  | 1,794 |  |  | 1,716 |  |  | 4.5 |
International |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Worldwide |  | 636 |  |  | 630 |  |  | 0.8 |  |  | 1,794 |  |  | 1,716 |  |  | 4.5 |
INVOKANA® / INVOKAMET® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 66 |  |  | 156 |  |  | (57.4) |  |  | 249 |  |  | 405 |  |  | (38.4) |
International |  | 67 |  |  | 68 |  |  | (1.0) |  |  | 194 |  |  | 173 |  |  | 11.9 |
Worldwide |  | 133 |  |  | 224 |  |  | (40.3) |  |  | 443 |  |  | 578 |  |  | (23.4) |
PROCRIT® / EPREX® |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 47 |  |  | 69 |  |  | (30.9) |  |  | 168 |  |  | 215 |  |  | (21.7) |
International |  | 65 |  |  | 63 |  |  | 3.1 |  |  | 198 |  |  | 208 |  |  | (4.7) |
Worldwide |  | 112 |  |  | 132 |  |  | (14.6) |  |  | 366 |  |  | 423 |  |  | (13.4) |
OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 51 |  |  | 75 |  |  | (32.6) |  |  | 168 |  |  | 238 |  |  | (29.3) |
International |  | 200 |  |  | 219 |  |  | (8.7) |  |  | 615 |  |  | 670 |  |  | (8.3) |
Worldwide |  | 251 |  |  | 294 |  |  | (14.8) |  |  | 783 |  |  | 908 |  |  | (13.8) |
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 7,221 |  |  | 6,438 |  |  | 12.2 |  |  | 20,536 |  |  | 18,619 |  |  | 10.3 |
International |  | 5,773 |  |  | 4,980 |  |  | 15.9 |  |  | 17,256 |  |  | 14,685 |  |  | 17.5 |
Worldwide |  | 12,994 |  |  | 11,418 |  |  | 13.8 |  |  | 37,792 |  |  | 33,304 |  |  | 13.5 |
MEDICAL DEVICES |  |  |  |  |  |  |  |  |  |  |  |
Interventional Solutions |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 444 |  |  | 399 |  |  | 11.1 |  |  | 1,353 |  |  | 1,019 |  |  | 32.7 |
International |  | 513 |  |  | 437 |  |  | 17.7 |  |  | 1,599 |  |  | 1,134 |  |  | 41.1 |
Worldwide |  | 957 |  |  | 836 |  |  | 14.5 |  |  | 2,952 |  |  | 2,153 |  |  | 37.1 |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,249 |  |  | 1,308 |  |  | (4.5) |  |  | 3,821 |  |  | 3,427 |  |  | 11.5 |
International |  | 843 |  |  | 774 |  |  | 8.8 |  |  | 2,611 |  |  | 2,145 |  |  | 21.7 |
Worldwide |  | 2,093 |  |  | 2,083 |  |  | 0.5 |  |  | 6,433 |  |  | 5,572 |  |  | 15.4 |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 210 |  |  | 221 |  |  | (5.3) |  |  | 654 |  |  | 564 |  |  | 15.9 |
International |  | 146 |  |  | 124 |  |  | 18.8 |  |  | 451 |  |  | 344 |  |  | 31.3 |
Worldwide |  | 356 |  |  | 345 |  |  | 3.3 |  |  | 1,105 |  |  | 908 |  |  | 21.8 |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 184 |  |  | 205 |  |  | (9.8) |  |  | 579 |  |  | 527 |  |  | 10.0 |
International |  | 131 |  |  | 102 |  |  | 28.1 |  |  | 403 |  |  | 298 |  |  | 35.4 |
Worldwide |  | 316 |  |  | 308 |  |  | 2.8 |  |  | 983 |  |  | 825 |  |  | 19.2 |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 455 |  |  | 433 |  |  | 5.3 |  |  | 1,352 |  |  | 1,194 |  |  | 13.3 |
International |  | 260 |  |  | 253 |  |  | 2.4 |  |  | 805 |  |  | 698 |  |  | 15.2 |
Worldwide |  | 715 |  |  | 685 |  |  | 4.2 |  |  | 2,157 |  |  | 1,892 |  |  | 14.0 |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 400 |  |  | 449 |  |  | (11.1) |  |  | 1,236 |  |  | 1,142 |  |  | 8.2 |
International |  | 306 |  |  | 295 |  |  | 3.5 |  |  | 952 |  |  | 805 |  |  | 18.2 |
Worldwide |  | 705 |  |  | 745 |  |  | (5.3) |  |  | 2,187 |  |  | 1,947 |  |  | 12.3 |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 948 |  |  | 913 |  |  | 3.9 |  |  | 2,881 |  |  | 2,247 |  |  | 28.2 |
International |  | 1,457 |  |  | 1,239 |  |  | 17.6 |  |  | 4,418 |  |  | 3,556 |  |  | 24.2 |
Worldwide |  | 2,405 |  |  | 2,152 |  |  | 11.8 |  |  | 7,299 |  |  | 5,803 |  |  | 25.8 |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 440 |  |  | 421 |  |  | 4.6 |  |  | 1,304 |  |  | 1,079 |  |  | 20.9 |
International |  | 705 |  |  | 579 |  |  | 21.8 |  |  | 2,126 |  |  | 1,644 |  |  | 29.3 |
Worldwide |  | 1,144 |  |  | 1,000 |  |  | 14.6 |  |  | 3,430 |  |  | 2,723 |  |  | 26.0 |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 508 |  |  | 492 |  |  | 3.3 |  |  | 1,577 |  |  | 1,168 |  |  | 35.0 |
International |  | 752 |  |  | 660 |  |  | 13.9 |  |  | 2,292 |  |  | 1,912 |  |  | 19.9 |
Worldwide |  | 1,261 |  |  | 1,152 |  |  | 9.4 |  |  | 3,869 |  |  | 3,080 |  |  | 25.6 |
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 475 |  |  | 473 |  |  | 0.6 |  |  | 1,414 |  |  | 1,160 |  |  | 21.9 |
International |  | 714 |  |  | 608 |  |  | 17.4 |  |  | 2,103 |  |  | 1,683 |  |  | 25.0 |
Worldwide |  | 1,189 |  |  | 1,081 |  |  | 10.1 |  |  | 3,517 |  |  | 2,843 |  |  | 23.7 |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 359 |  |  | 375 |  |  | (4.3) |  |  | 1,082 |  |  | 924 |  |  | 17.0 |
International |  | 522 |  |  | 455 |  |  | 14.9 |  |  | 1,525 |  |  | 1,274 |  |  | 19.8 |
Worldwide |  | 882 |  |  | 830 |  |  | 6.2 |  |  | 2,607 |  |  | 2,198 |  |  | 18.6 |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 117 |  |  | 98 |  |  | 19.6 |  |  | 333 |  |  | 236 |  |  | 41.1 |
International |  | 191 |  |  | 153 |  |  | 24.7 |  |  | 577 |  |  | 409 |  |  | 41.1 |
Worldwide |  | 308 |  |  | 251 |  |  | 22.7 |  |  | 910 |  |  | 645 |  |  | 41.1 |
TOTAL MEDICAL DEVICES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,117 |  |  | 3,092 |  |  | 0.8 |  |  | 9,470 |  |  | 7,852 |  |  | 20.6 |
International |  | 3,527 |  |  | 3,058 |  |  | 15.4 |  |  | 10,731 |  |  | 8,518 |  |  | 26.0 |
Worldwide |  | 6,644 |  |  | 6,150 |  |  | 8.0 |  |  | 20,201 |  |  | 16,370 |  |  | 23.4 |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 11,963 |  |  | 11,086 |  |  | 7.9 |  |  | 34,993 |  |  | 31,324 |  |  | 11.7 |
International |  | 11,375 |  |  | 9,996 |  |  | 13.8 |  |  | 33,978 |  |  | 28,785 |  |  | 18.0 |
Worldwide |  | $ | 23,338 |  |  | 21,082 |  |  | 10.7 | % |  | $ | 68,971 |  |  | 60,109 |  |  | 14.7 | %
*Percentage greater than 100% or not meaningful (1) Inclusive of VELCADE® which was previously disclosed separately
Operating Profit by Segment of Business | EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended |
(Dollars in Millions) |  | October 3, 2021 |  | September 27, 2020 |  | Percent Change |  | October 3, 2021 |  | September 27, 2020 |  | Percent Change |  |  |  |  |
Consumer Health (1) |  | $ | (636) |  |  | 191 |  |  | * |  | $ | 956 |  |  | 993 |  |  | (3.7)% |  |  |  |  |
Pharmaceutical(2) |  | 4,259 |  |  | 3,439 |  |  | 23.8 |  | 13,838 |  |  | 11,787 |  |  | 17.4 |  |  |  |  |
Medical Devices(3) |  | 423 |  |  | 1,010 |  |  | (58.1) |  | 3,798 |  |  | 2,681 |  |  | 41.7 |  |  |  |  |
Segment earnings before provision for taxes |  | 4,046 |  |  | 4,640 |  |  | (12.8) |  | 18,592 |  |  | 15,461 |  |  | 20.3 |  |  |  |  |
Less: Expense not allocated to segments (4) |  | 197 |  |  | 239 |  |  |  |  | 652 |  |  | 611 |  |  |  |  |  |  |  |
Worldwide income before tax |  | $ | 3,849 |  |  | 4,401 |  |  | (12.5)% |  | $ | 17,940 |  |  | 14,850 |  |  | 20.8% |  |  |  |  |
*Percentage greater than 100% or not meaningful (1) Consumer Health •Includes intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2021 and 2020 and $0.3 billion in both the fiscal nine months of 2021 and 2020. •Includes litigation expense of $1.4 billion and $0.5 billion in the fiscal third quarter of 2021 and 2020, respectively. Includes litigation expense of $1.5 billion and $1.2 billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in both periods is primarily related to talc. •Includes a restructuring related charge of $0.1 billion in both the fiscal nine months of 2021 and 2020. (2) Pharmaceutical •Includes divestiture gains of $0.6 billion in the fiscal nine months of 2021 related to two brands outside the U.S. •Includes intangible amortization expense of $0.8 billion in both the fiscal third quarter of 2021 and 2020. Includes intangible amortization expense of $2.5 billion and $2.4 billion in the fiscal nine months of 2021 and 2020, respectively. •Includes net litigation expense of $0.8 billion and $1.0 billion in the fiscal third quarter of 2021 and 2020, respectively. Includes net litigation expense of $0.7 billion and $1.0 billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in 2021 is primarily related to Risperdal. Litigation expense in 2020 is related to the opioid settlement. •Includes a gain on securities of $0.1 billion in the fiscal third quarter of 2021 and $0.2 billion in both the fiscal nine months of 2021 and 2020, respectively. •Includes a restructuring related charge of $0.1 billion in both the fiscal nine months of 2021 and 2020, respectively. In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.2 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) Medical Devices •Includes a contingent consideration reversal of $0.2 billion in the fiscal third quarter of 2020 and $1.1 billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. •Includes a restructuring related charge of $0.1 billion in both the fiscal third quarter of 2021 and 2020, respectively. Includes a restructuring related charge of $0.2 billion in both the fiscal nine months of 2021 and 2020, respectively. •Includes intangible amortization expense of $0.3 billion and $0.2 billion in the fiscal third quarter of 2021 and 2020, respectively. Includes intangible amortization expense of $0.8 billion and $0.7 billion in the fiscal nine months of 2021 and 2020, respectively. •Includes a gain on securities of $0.1 billion in the fiscal nine months of 2021. •Includes an in-process research and development expense of $0.9 billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. See Note 3 to the Consolidated Financial Statements for more details. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. | EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended |
(Dollars in Millions) |  | October 3, 2021 |  | September 27, 2020 |  | Percent Change |  | October 3, 2021 |  | September 27, 2020 |  | Percent Change |  |  |  |  |
Consumer Health (1) |  | $ | (636) |  |  | 191 |  |  | * |  | $ | 956 |  |  | 993 |  |  | (3.7)% |  |  |  |  |
Pharmaceutical(2) |  | 4,259 |  |  | 3,439 |  |  | 23.8 |  | 13,838 |  |  | 11,787 |  |  | 17.4 |  |  |  |  |
Medical Devices(3) |  | 423 |  |  | 1,010 |  |  | (58.1) |  | 3,798 |  |  | 2,681 |  |  | 41.7 |  |  |  |  |
Segment earnings before provision for taxes |  | 4,046 |  |  | 4,640 |  |  | (12.8) |  | 18,592 |  |  | 15,461 |  |  | 20.3 |  |  |  |  |
Less: Expense not allocated to segments (4) |  | 197 |  |  | 239 |  |  |  |  | 652 |  |  | 611 |  |  |  |  |  |  |  |
Worldwide income before tax |  | $ | 3,849 |  |  | 4,401 |  |  | (12.5)% |  | $ | 17,940 |  |  | 14,850 |  |  | 20.8% |  |  |  |  |
*Percentage greater than 100% or not meaningful (1) Consumer Health •Includes intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2021 and 2020 and $0.3 billion in both the fiscal nine months of 2021 and 2020. •Includes litigation expense of $1.4 billion and $0.5 billion in the fiscal third quarter of 2021 and 2020, respectively. Includes litigation expense of $1.5 billion and $1.2 billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in both periods is primarily related to talc. •Includes a restructuring related charge of $0.1 billion in both the fiscal nine months of 2021 and 2020. (2) Pharmaceutical •Includes divestiture gains of $0.6 billion in the fiscal nine months of 2021 related to two brands outside the U.S. •Includes intangible amortization expense of $0.8 billion in both the fiscal third quarter of 2021 and 2020. Includes intangible amortization expense of $2.5 billion and $2.4 billion in the fiscal nine months of 2021 and 2020, respectively. •Includes net litigation expense of $0.8 billion and $1.0 billion in the fiscal third quarter of 2021 and 2020, respectively. Includes net litigation expense of $0.7 billion and $1.0 billion in the fiscal nine months of 2021 and 2020, respectively. Litigation expense in 2021 is primarily related to Risperdal. Litigation expense in 2020 is related to the opioid settlement. •Includes a gain on securities of $0.1 billion in the fiscal third quarter of 2021 and $0.2 billion in both the fiscal nine months of 2021 and 2020, respectively. •Includes a restructuring related charge of $0.1 billion in both the fiscal nine months of 2021 and 2020, respectively. In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.2 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) Medical Devices •Includes a contingent consideration reversal of $0.2 billion in the fiscal third quarter of 2020 and $1.1 billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. •Includes a restructuring related charge of $0.1 billion in both the fiscal third quarter of 2021 and 2020, respectively. Includes a restructuring related charge of $0.2 billion in both the fiscal nine months of 2021 and 2020, respectively. •Includes intangible amortization expense of $0.3 billion and $0.2 billion in the fiscal third quarter of 2021 and 2020, respectively. Includes intangible amortization expense of $0.8 billion and $0.7 billion in the fiscal nine months of 2021 and 2020, respectively. •Includes a gain on securities of $0.1 billion in the fiscal nine months of 2021. •Includes an in-process research and development expense of $0.9 billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021. See Note 3 to the Consolidated Financial Statements for more details. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas |  | SALES BY GEOGRAPHIC AREA
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | October 3, 2021 |  | September 27, 2020 |  | Percent Change |  | October 3, 2021 |  | September 27, 2020 |  | Percent Change
United States |  | $ | 11,963 |  |  | 11,086 |  |  | 7.9 | % |  | $ | 34,993 |  |  | 31,324 |  |  | 11.7 | %
Europe |  | 5,587 |  |  | 4,819 |  |  | 15.9 |  |  | 16,669 |  |  | 13,709 |  |  | 21.6 |
Western Hemisphere, excluding U.S. |  | 1,500 |  |  | 1,296 |  |  | 15.7 |  |  | 4,291 |  |  | 3,931 |  |  | 9.2 |
Asia-Pacific, Africa |  | 4,288 |  |  | 3,881 |  |  | 10.5 |  |  | 13,018 |  |  | 11,145 |  |  | 16.8 |
Total |  | $ | 23,338 |  |  | 21,082 |  |  | 10.7 | % |  | $ | 68,971 |  |  | 60,109 |  |  | 14.7 | %

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration